| |
|
Open Monoclonal Technology, Inc.
OMT is developing a transgenic rat for the generation of fully human antibodies.
This new technology is the result of breakthroughs in the understanding of B-cell development and a novel approach to the inactivation of endogenous
antibody expression.
OMT's antibody platform has broad freedom to operate and uses technology protected by patents. Founded in 2007, the company has achieved
significant technical milestones and is on track to produce human antibodies by 2010.
OMT is funded by Essex Woodlands Health Ventures, one the oldest, largest and most respected healthcare venture companies.
|
|
|
|
